128 related articles for article (PubMed ID: 17442068)
1. Possible therapeutic effect of lipid supplementation on neurological complications in liver transplant recipients.
Ide K; Ohdan H; Tahara H; Ishiyama K; Shishida M; Irei T; Ohira M; Tashiro H; Itamoto T; Asahara T
Transpl Int; 2007 Jul; 20(7):632-5. PubMed ID: 17442068
[TBL] [Abstract][Full Text] [Related]
2. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation.
Forgacs B; Merhav HJ; Lappin J; Mieles L
Transplant Proc; 2005 May; 37(4):1912-4. PubMed ID: 15919502
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
4. Impaired erythropoietin production in liver transplant recipients: the role of calcineurin inhibitors.
Bardet V; Junior AP; Coste J; Lecoq-Lafon C; Chouzenoux S; Bernard D; Soubrane O; Lacombe C; Calmus Y; Conti F
Liver Transpl; 2006 Nov; 12(11):1649-54. PubMed ID: 17058250
[TBL] [Abstract][Full Text] [Related]
5. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
8. Calcineurin inhibitors in heart transplantation.
Crespo-Leiro MG
Transplant Proc; 2005 Nov; 37(9):4018-20. PubMed ID: 16386614
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction due to calcineurin inhibitors.
Di Benedetto F; Di Sandro S; De Ruvo N; Spaggiari M; Montalti R; Ballarin R; Cappelli G; Gerunda GE
J Clin Gastroenterol; 2009 Mar; 43(3):280-6. PubMed ID: 19057397
[TBL] [Abstract][Full Text] [Related]
10. [Controversies about the use of calcineurin inhibitors in pediatric patients].
Dello Strologo L
G Ital Nefrol; 2008; 25(3):317-24. PubMed ID: 18473303
[TBL] [Abstract][Full Text] [Related]
11. Avoiding calcineurin inhibitors in the early post-operative course in high-risk liver transplant recipients: The role of extracorporeal photopheresis.
Urbani L; Mazzoni A; De Simone P; Catalano G; Coletti L; Petruccelli S; Biancofiore G; Bindi L; Scatena F; Filipponi F
J Clin Apher; 2007; 22(4):187-94. PubMed ID: 17294458
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
[TBL] [Abstract][Full Text] [Related]
13. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients.
Mori T; Aisa Y; Kato J; Nakamura Y; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2009 Sep; 44(6):371-4. PubMed ID: 19270729
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with response to calcineurin inhibitors in myasthenia gravis.
Nagane Y; Suzuki S; Suzuki N; Utsugisawa K
Muscle Nerve; 2010 Feb; 41(2):212-8. PubMed ID: 19816912
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic monitoring of calcineurin inhibitors for the nephrologist.
Schiff J; Cole E; Cantarovich M
Clin J Am Soc Nephrol; 2007 Mar; 2(2):374-84. PubMed ID: 17699437
[TBL] [Abstract][Full Text] [Related]
16. Calcineurin inhibitors: 40 years later, can't live without ..
Azzi JR; Sayegh MH; Mallat SG
J Immunol; 2013 Dec; 191(12):5785-91. PubMed ID: 24319282
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level.
Calvo-Turrubiartes M; Romano-Moreno S; García-Hernández M; Chevaile-Ramos JA; Layseca-Espinosa E; González-Amaro R; Portales-Pérez D
Transpl Immunol; 2009 May; 21(1):43-9. PubMed ID: 19233271
[TBL] [Abstract][Full Text] [Related]
18. Cerebellar ataxia in a patient receiving calcineurin inhibitors after living donor liver transplantation: a case report.
Yamaguchi I; Ichikawa T; Nakao K; Hamasaki K; Hirano K; Eguchi S; Takatsuki M; Kawasita Y; Kanematsu T; Eguchi K
Transplant Proc; 2007 Dec; 39(10):3495-7. PubMed ID: 18089418
[TBL] [Abstract][Full Text] [Related]
19. Neurological complications after liver transplantation as a consequence of immunosuppression: univariate and multivariate analysis of risk factors.
Rompianesi G; Montalti R; Cautero N; De Ruvo N; Stafford A; Bronzoni C; Ballarin R; De Pietri L; Di Benedetto F; Gerunda GE
Transpl Int; 2015 Jul; 28(7):864-9. PubMed ID: 25790037
[TBL] [Abstract][Full Text] [Related]
20. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
